Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly 2005 Sales Growth Will Rest On Strength Of New Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the eight products that Lilly has launched since November 2001 are projected to account for 20% of total sales, CFO Golden tells analysts. Lilly expects Yentreve (duloxetine) to win FDA approval for stress urinary incontinence in the first half of 2005.

You may also be interested in...



Lilly Withdraws Yentreve NDA One Day Ahead Of Expected Negative Review

Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.

Lilly Withdraws Yentreve NDA One Day Ahead Of Expected Negative Review

Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.

Yentreve Launch Will Be Slowed By Poor Patient Awareness, Lilly Predicts

Lilly expects its launch of Yentreve (duloxetine) will be slowed by a lack of patient awareness about the stress urinary incontinence treatment

Related Content

Topics

UsernamePublicRestriction

Register

PS058559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel